Home

James M Daly

CIK 1560782 · EVP, Chief Commercial Officer · last filed 2026-07-16

James M Daly is an EVP, Chief Commercial Officer who has filed 81 SEC Form 4 insider transactions across 7 companies since 2012. The most recent filing shows the insider was granted $12.5K of CYTK on Jul 16, 2026. Across all open-market trades the lifetime net is −$41.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.5M across reported positions. 20 SEC filings were submitted jointly with INCYTE CORP.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.51M

Companies

7

Total Filings

81

Lifetime Open-Market Net

-$41.76M

Filer Profile

Reported Address
INCYTE CORPORATION EXPERIMENTAL STATION
RTE 141 & HENRY CLAY RD. BLDG E336
WILMINGTON, DE 19880
Related Filers
INCYTE CORP — 20 joint filings, latest 2015-06-25
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CYTK Director 3,390 $64.53 $218.8K $0 5 2026-07-16
MDGL Director 3,081 $520.04 $1.60M -$13.59M 10 2026-06-18
ACAD Director 12,148 $20.73 $251.9K -$3.15M 16 2026-06-01
HALOZYME THERAPEUTICS, INC. (HTI) Delisted Director 20,503 — — -$2.29M 11 2023-08-15
BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted Director 109,873 $0.07 $8.2K $0 13 2023-01-05
CHIMERIX INC (CMRX) Delisted Director — $8.54 — $0 5 2019-06-24
INCY EVP, Chief Commercial Officer 3,521 $124.64 $438.8K -$22.72M 16 2015-06-25

Recent Filings

81 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-16 CYTK Grant (A) +151 $12.5K EDGAR
2026-06-18 MDGL Grant (A) +454 $0 EDGAR
2026-06-01 ACAD Mixed +8,107 $0 EDGAR
2026-05-27 CYTK Grant (A) +2,851 $0 EDGAR
2026-04-15 CYTK Grant (A) +191 $12.5K EDGAR
2026-01-20 CYTK Grant (A) +197 $12.5K EDGAR
2025-11-12 ACAD Sell (S) −30,000 -$671.0K EDGAR
2025-11-10 ACAD Notice (144) −30,000 -$671.0K EDGAR
2025-08-20 CYTK Grant (A) — $0 EDGAR
2025-06-24 MDGL Grant (A) +715 $0 EDGAR
Showing 1–10 of 81
Page 1 of 9
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.